VBL Therapeutics to Participate in the Jefferies Healthcare Conference

Rhea-AI Summary

VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotech firm focused on innovative treatments for challenging cancers and inflammatory conditions, will showcase its corporate overview at the Jefferies Healthcare Conference in New York on June 8-10, 2022. Dror Harats, M.D., CEO of VBL, will present on June 8 at 3:00 p.m. ET. Investors can access a replay of the webcast for 90 days on VBL's website after the event. VBL is advancing its lead oncology candidate, ofra-vec, currently in a Phase 3 trial for platinum-resistant ovarian cancer.

TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview and participate in investor meetings at the upcoming Jefferies Healthcare Conference being held in New York on June 8 – 10, 2022.

Jefferies Healthcare Conference
Date: Wednesday, June 8^th, 2022
Time: 3:00 p.m. ET
Format: Corporate Overview
Webcast Link

A replay of the webcast will be available following the presentation for 90 days on the Events and Presentations page of the Investors section on the Company’s website at www.vblrx.com.

About VBL Therapeutics
Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a late clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. Using our novel platform technologies, we have created a pipeline of therapeutics to uniquely address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of currently approved treatments. Our product candidates are built off of our two platform technologies: Vascular Targeting System (VTS™), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. Our lead oncology product candidate, ofra-vec (ofranergene obadenovec; `VB-111`), is an investigational targeted anti-cancer gene-based agent in development to treat a wide range of solid tumors. Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer. To learn more about VBL, please visit vblrx.com or follow VBL on LinkedIn, Twitter, YouTube or Facebook.

CONTACT:
Daniel Ferry LifeSci Advisors +1 (617) 430-7576 daniel@lifesciadvisors.com

FAQ

What is VBL Therapeutics presenting at the Jefferies Healthcare Conference?

VBL Therapeutics will present a corporate overview at the Jefferies Healthcare Conference in New York on June 8, 2022.

When is VBL Therapeutics's presentation at the Jefferies Healthcare Conference?

The presentation will take place on June 8, 2022, at 3:00 p.m. ET.

How can I access VBL Therapeutics's presentation after the Jefferies Healthcare Conference?

A replay of VBL Therapeutics's presentation will be available for 90 days on their website.

What is ofra-vec and its significance for VBL Therapeutics?

Ofra-vec is VBL Therapeutics's lead oncology product candidate, currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.

What role does Dror Harats have at VBL Therapeutics?

Dror Harats is the Chief Executive Officer of VBL Therapeutics.